(2-Amino-4-cyanophenyl)boronic acid | 850689-37-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2-Amino-4-cyanophenyl)boronic acid
• CAS: 850689-37-1
• 化学式: C₇H₇BN₂O₂
• mdl: MFCD22570806
• 分子量: 161.956
• InChiKey: YNYMSUQBEHPULZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.67
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  90.3
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  (2-Amino-4-cyanophenyl)boronic acid 在 四(三苯基膦)钯 、 sodium hydride 、 caesium carbonate 作用下， 以 乙二醇二甲醚 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 32.0h， 生成 2-methoxy-3-[3-(4-methylpiperazin-1-yl)propoxy]-11H-indolo[3,2-c]quinoline-9-carbonitrile
  参考文献：
  名称：

  Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4

  摘要：

  IRAK4 is responsible for initiating signaling from Toll-like receptors (TLRs) and members of the IL-1/18 receptor family. Kinase-inactive knock-ins and targeted deletions of IRAK4 in mice cause reductions in TLR induced pro-inflammatory cytokines and these mice are resistant to various models of arthritis. Herein we report the identification and optimization of a series of potent IRAK4 inhibitors. Representative examples from this series showed excellent selectivity over a panel of kinases, including the kinases known to play a role in TLR-mediated signaling. The compounds exhibited low nM potency in LPSand R848-induced cytokine assays indicating that they are blocking the TLR signaling pathway. A key compound (26) from this series was profiled in more detail and found to have an excellent pharmaceutical profile as measured by predictive assays such as microsomal stability, TPSA, solubility, and clogP. However, this compound was found to afford poor exposure in mouse upon IP or IV administration. We found that removal of the ionizable solubilizing group (32) led to increased exposure, presumably due to increased permeability. Compounds 26 and 32, when dosed to plasma levels corresponding to ex vivo whole blood potency, were shown to inhibit LPS-induced TNF alpha in an in vivo murine model. To our knowledge, this is the first published in vivo demonstration that inhibition of the IRAK4 pathway by a small molecule can recapitulate the phenotype of IRAK4 knockout mice. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2014.03.056

文献信息

• Synthesis of benzofused 1,4-azaborinols via [4 + 2] annulation strategy and its application in indole synthesis
  作者：Murugan Chinnapattu、Kulathu Iyer Sathiyanarayanan、Pravin S. Iyer

  DOI：10.1039/c5ra05082k

  日期：——

  The first general synthesis of benzofused 1,4-azaborinols via [4 + 2] annulation strategy and its application in indole synthesis.

  通过[4 + 2]环化策略合成苯并1,4-氮硼醇的第一个通用合成方法及其在吲哚合成中的应用。
• Discovery of Imidazo[1,2-<i>b</i>]pyridazine Derivatives: Selective and Orally Available Mps1 (TTK) Kinase Inhibitors Exhibiting Remarkable Antiproliferative Activity
  作者：Ken-ichi Kusakabe、Nobuyuki Ide、Yataro Daigo、Takeshi Itoh、Takahiko Yamamoto、Hiroshi Hashizume、Kohei Nozu、Hiroshi Yoshida、Genta Tadano、Sachie Tagashira、Kenichi Higashino、Yousuke Okano、Yuji Sato、Makiko Inoue、Motofumi Iguchi、Takayuki Kanazawa、Yukichi Ishioka、Keiji Dohi、Yasuto Kido、Shingo Sakamoto、Shigeru Ando、Masahiro Maeda、Masayo Higaki、Yoshiyasu Baba、Yusuke Nakamura

  DOI：10.1021/jm501599u

  日期：2015.2.26

  Monopolar spindle 1 (Mps1) is an attractive oncology target due to its high expression level in cancer cells as well as the correlation of its expression levels with histological grades of cancers. An imidazo[1,2-a]pyrazine 10a was identified during an HTS campaign. Although 10a exhibited good biochemical activity, its moderate cellular as well as antiproliferative activities needed to be improved. The cocrystal structure of an analogue of 10a guided our lead optimization to introduce substituents at the 6-position of the scaffold, giving the 6-aryl substituted 21b which had improved cellular activity but no oral bioavailability in rat. Property-based optimization at the 6-position and a scaffold change led to the discovery of the imidazo[1,2-b]pyridazine-based 27f, an extremely potent (cellular Mps1 IC50 = 0.70 nM, A549 IC50 = 6.0 nM), selective Mps1 inhibitor over 192 kinases, which could be orally administered and was active in vivo. This 27f demonstrated remarkable antiproliferative activity in the nanomolar range against various tissue cancer cell lines.
• Identification and optimization of indolo[2,3-c]quinoline inhibitors of IRAK4
  作者：L. Nathan Tumey、Diane H. Boschelli、Niala Bhagirath、Jaechul Shim、Elizabeth A. Murphy、Deborah Goodwin、Eric M. Bennett、Mengmeng Wang、Lih-Ling Lin、Barry Press、Marina Shen、Richard K. Frisbie、Paul Morgan、Shashi Mohan、Julia Shin、Vikram R. Rao

  DOI：10.1016/j.bmcl.2014.03.056

  日期：2014.5

  IRAK4 is responsible for initiating signaling from Toll-like receptors (TLRs) and members of the IL-1/18 receptor family. Kinase-inactive knock-ins and targeted deletions of IRAK4 in mice cause reductions in TLR induced pro-inflammatory cytokines and these mice are resistant to various models of arthritis. Herein we report the identification and optimization of a series of potent IRAK4 inhibitors. Representative examples from this series showed excellent selectivity over a panel of kinases, including the kinases known to play a role in TLR-mediated signaling. The compounds exhibited low nM potency in LPSand R848-induced cytokine assays indicating that they are blocking the TLR signaling pathway. A key compound (26) from this series was profiled in more detail and found to have an excellent pharmaceutical profile as measured by predictive assays such as microsomal stability, TPSA, solubility, and clogP. However, this compound was found to afford poor exposure in mouse upon IP or IV administration. We found that removal of the ionizable solubilizing group (32) led to increased exposure, presumably due to increased permeability. Compounds 26 and 32, when dosed to plasma levels corresponding to ex vivo whole blood potency, were shown to inhibit LPS-induced TNF alpha in an in vivo murine model. To our knowledge, this is the first published in vivo demonstration that inhibition of the IRAK4 pathway by a small molecule can recapitulate the phenotype of IRAK4 knockout mice. (C) 2014 Elsevier Ltd. All rights reserved.